|Myrexis Announces Executive Management Changes.|
|By Staff and Wire Reports|
|Friday, 22 July 2011 19:07|
Myrexis, Inc. (Public, NASDAQ:MYRX) announced Adrian N. Hobden, Ph.D. has resigned as President, Chief Executive Officer and a member of the Board of Directors, effective July 21, 2011.
The Board of Directors has appointed Robert J. Lollini, the Company's Chief Financial Officer, as interim President and Chief Executive Officer. Mr. Lollini will also continue has duties as Chief Financial Officer. The Board plans to initiate a search for a new CEO, looking at both internal and external candidates. In addition, Dr. Hobden has agreed to serve as a consultant to the Company for three months to assist in the transition.
ERT (NASDAQ:ERT) announced today that it will release its operating results for the second quarter 2011 Monday, August 1, after the market closes.
MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial-based products and bioimplants processed from human amniotic membrane, announced today that its results for the second quarter, ended June 30, 2011, will be released before the opening of the market on Monday, July 25, 2011.
NeurogesX, Inc. (Nasdaq:NGSX), a biopharmaceutical company focused on developing novel pain management therapies, today announced that on July 21, 2011 it entered into a securities purchase agreement in connection with a private placement to a group of institutional accredited investors and, subject to standard closing conditions, is expected to receive approximately $20 million in gross proceeds from the sale of 11,749,552 shares of its common stock and the issuance of five-year warrants to purchase 5,874,782 additional shares of NGSX common stock at an exercise price of $1.65 per share.
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the cobas KRAS Mutation Test is now commercially available in Europe for use in colorectal cancer.
Sigma Life Science, the innovative biological products and services research business of Sigma-Aldrich® (Nasdaq:SIAL), today announced the expansion of its CompoZr® Oncology Disease Model portfolio with the release of the first in its collection of breast cancer-specific knockout and knockin cell lines for drug discovery and research.
Tianyin Pharmaceutical Co., Inc. (NYSE Amex:TPI), a pharmaceutical company that specializes in the research, development and sale of patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and active pharmaceutical ingredients (API) today announced that the Company has shipped the first batch of Azithromycin API sample to RELATIONS International Ltd. for Bangladesh export standard test.